- Patient groups and indications where low molecular weight heparin products need to be used
- Patient groups and indications where low molecular weight heparin products can be substituted with unfractionated heparin and/or warfarin and/or other anticoagulants such as fondaparinux
- Patient groups and indications where anticoagulants can be substituted with alternative measures such as graduated compression stockings (GCSs) and mechanical calf compression
- Patient groups and indications which can be deferred or delayed without risk to patient safety
From the evidence-based guidelines for antithrombotic and thrombolytic therapy used by Australian clinicians (Appendix 1) and other peer-reviewed publications, the AHPC group has assembled detailed information on alternative products and therapies and how they may be used, including substitution regimens (Appendix 2).
The prioritisation schema of heparin based products according to clinical need is outlined in further detail in Appendix 3.
This publication is available as a downloadable document.